Future growth expectations in sales/revenue/volumes?

Calquence has generated $173 million in worldwide sales since its launch in November 2017. (Page 22) There are ongoing Phase III trials and regulatory submissions expected to expand indications and markets, including: - ACE-CL-309 ASCEND in relapsed/refractory CLL (Approved in US) - ACE-CL-007 ELEVATE TN in previously-untreated CLL (Approved in US) - Calquence regulatory submissions in EU and Japan targeted for H1 2020 - ACE-CL-006 ELEVATE RR in relapsed/refractory high-risk CLL with data expected 2021+ - ACE CL-311 for previously-untreated CLL (with venetoclax) with data

Astrazeneca Pharma India LtdQ2 FY20Pharmaceuticals & Biotechnology

Astrazeneca Pharma India Ltd Q2 FY20 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹6,031P/E: 93.7Market Cap: ₹16.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Calquence has generated $173 million in worldwide sales since its launch in November 2017. (Page 22)
There are ongoing Phase III trials and regulatory submissions expected to expand indications and markets, including:
- ACE-CL-309 ASCEND in relapsed/refractory CLL (Approved in US)
- ACE-CL-007 ELEVATE TN in previously-untreated CLL (Approved in US)
- Calquence regulatory submissions in EU and Japan targeted for H1 2020
- ACE-CL-006 ELEVATE RR in relapsed/refractory high-risk CLL with data expected 2021+
- ACE CL-311 for previously-untreated CLL (with venetoclax) with data expected 2021+
Approximately 28,000 total patients in the US and EU treated or eligible (17,000 front-line; 11,000 relapsed/refractory). (Page 22)
Positive Phase III data readouts in CLL create momentum for future growth.

Margin guidance

The provided pages do not include explicit future growth expectations specifically for earnings, operating earnings, profits, or EPS of AstraZeneca. However, some related insights are: - Forward-looking statements highlight risks and uncertainties affecting financial performance, including patent expirations, R&D outcomes, competition, regulatory approvals, and global economic conditions (Page 2). - The document notes momentum from Phase III data readouts in CLL, with ongoing trials and regulatory submissions supporting future growth potential (Page 22). - Calquence sales since launch reached $173m globally, with expansion expected due to additional pivotal trials and approvals (Page 22). - No direct quantified forecasts for earnings or EPS are provided. - AstraZeneca disclaims this presentation/webcast as a profit forecast (Page 2). For precise future earnings or EPS growth projections, please refer to dedicated financial reports or investor guidance from AstraZeneca.

See what Astrazeneca Pharma India Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The provided document (310.pdf) does not contain any information regarding current or future fundraising efforts by AstraZeneca through debt or equity. The content mainly focuses on: - Clinical trial data and updates for Calquence in CLL (chronic lymphocytic leukemia) - Safety and efficacy results from the Phase III ELEVATE TN trial - Presentation and conference call use restrictions - Forward-looking statements caution - Company sales figures and trial status updates No sections mention plans or activities related to raising capital via debt or equity issuance.

Order book

The provided pages from the document "310.pdf" do not contain any information regarding the current or expected order book or pending orders for AstraZeneca. The content mainly focuses on: - Details about the Calquence Phase III ELEVATE TN trial for chronic lymphocytic leukemia (CLL), including efficacy, safety, patient demographics, and trial design. - AstraZeneca’s use of their conference materials. - Presentations and abstracts related to hematology and oncology areas at scientific meetings. - Forward-looking statements about business risks and factors. No financial data or order book information is presented in the provided pages.

See what Astrazeneca Pharma India Ltd management said on order book — free account, 30 seconds.

Capex plans

The provided pages of the AstraZeneca ASH 2019 presentation (310.pdf) do not explicitly mention any current or future capital expenditure (capex), capital investments, or strategic investments. The focus is mainly on: - Clinical trial updates for Calquence in CLL (ELEVATE TN, ASCEND trials). - Product pipeline progress including new agents (AZD5991, AZD4573, AZD2811, AZD0466). - Regulatory submissions planned in H1 2020. - Sales performance and patient numbers. - Safety and efficacy data from trials. - Forward-looking statements highlighting general risks but no specific capex plans. No direct references to capex, capital investment plans, or strategic investments are detailed in the provided content.

Track Astrazeneca Pharma India Ltd — get its next earnings analysis in your feed

How does Astrazeneca Pharma India Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAstrazeneca Pharma India Ltd

See where Astrazeneca Pharma India Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Astrazeneca Pharma India Ltd rank in Pharmaceuticals & Biotechnology?

Compare Astrazeneca Pharma India Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY20) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Astrazeneca Pharma India Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →